With morale at a low point, biotech and pharma CEOs are cautiously optimistic about the incoming Trump administration.

It’s not just the tech billionaires descending on Washington. Plenty of chief executives from other industries are also ...

Washington, DC, is set to host the inauguration of Donald Trump's second term, featuring wealthy supporters like Elon Musk, ...

Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.

Topics up for discussion range from carbon pricing and the economics of nature to changing weather patterns and upcoming ...

The World Economic Forum’s Annual Meeting agenda promises to cover sustainability and energy issues from the environment to people and new technologies ...

Dealmaking, deregulation and threats to global trade are expected to dominate the conversation among executives gathering in Davos this week, as Donald Trump’s return to the White House shifts the ...

Riley Wealth Management chief market strategist Art Hogan discusses whether the Fed's interest rate move changed his investment focus on 'The Claman Countdown.' Euro Pacific Capital chief economist ...

FDA Commissioner Robert Califf is closing the book on his second stint leading the agency that regulates products accounting ...

Of the 24 analysts covering Pfizer, 11 have a “Strong Buy” rating while 12 rate it as a “Hold” or some equivalent. One ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Artbio, a clinical-stage radiopharmaceutical company, named Johnson & Johnson alum Margaret Yu as chief medical officer. Saisei Ventures tapped Dr. Sven Kili as partner. OSE Immunotherapeutics ...